TWST Earnings Date: Nov 12, 2026 (Estimated) — Twist Bioscience Corporation
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is TWST's next earnings date?
Twist Bioscience Corporation (TWST) is expected to report Q4 2026 earnings on Thursday, November 12, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.38 on revenue of $123.6M.
How did TWST do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q3 2026), Twist Bioscience Corporation posted EPS of -$0.56 versus the -$0.24 estimate, a miss of 133.3%. Revenue was $118.4M against a $114.5M estimate. The stock's 1-day post-earnings move was +10.4%.
How much does TWST stock move after earnings?
TWST beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.5% (up or down) in the day after earnings.
About Twist Bioscience Corporation
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q3 2026 | -0.24 | -0.56 | -133.33% | $118.4M | ❌ Miss | +10.39% | +26.35% | +51.83% |
| 2026-05-04 | Q2 2026 | -0.53 | -0.59 | -11.32% | $110.7M | ❌ Miss | -6.97% | -5.88% | +16.14% |
| 2026-02-02 | Q1 2026 | -0.50 | -0.50 | +0.00% | $103.7M | ➖ Inline | +13.98% | +19.89% | +13.59% |
| 2025-11-14 | Q4 2025 | -0.46 | -0.45 | +2.17% | $99.0M | ✅ Beat | -10.13% | -12.81% | +3.91% |
| 2025-08-04 | Q3 2025 | -0.56 | -0.47 | +16.07% | $96.1M | ✅ Beat | -10.30% | -23.87% | -22.09% |
| 2025-02-03 | Q1 2025 | -0.63 | -0.53 | +15.87% | $88.7M | ✅ Beat | +0.73% | -0.13% | -24.23% |
| 2024-11-18 | Q4 2024 | -0.69 | -0.59 | +14.49% | $84.7M | ✅ Beat | +12.31% | +14.48% | +31.20% |
| 2024-08-02 | Q3 2024 | -0.77 | -0.70 | +9.09% | $81.5M | ✅ Beat | -19.00% | -14.38% | -18.49% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $118.4M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Ngs Tools | 52.2% | $61.8M | +11.8% | $48.6M | $51.1M | $55.3M | $53.0M |
| Antibody Discovery | 47.8% | $56.6M | +907.7% | $5.7M | $5.7M | $5.6M | $6.4M |
By region
Q3 FY26 · $118.4M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 65.3% | $77.3M | +30.1% | $53.7M | $55.2M | $59.4M | $57.3M |
| EMEA | 28.4% | $33.6M | +9.4% | $28.3M | $30.6M | $30.7M | $34.6M |
| Asia Pacific | 6.3% | $7.5M | +26.4% | $6.7M | $7.0M | $5.9M | $7.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.